Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits

Yoo, Ae Ri; Chung, Sung Kun

doi:10.1097/ico.0000000000000220

Cited by 17 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the corneal inflammation score and corneal VEGF levels were significantly lower . In addition, compared with bevacizumab, subconjunctival injection of 2.5 mg tocilizumab showed similar effect of decreasing CNV under the same dosage …”

Section: The Drug Treatment Of Cnvmentioning

confidence: 85%

“…[35] In addition, compared with bevacizumab, subconjunctival injection of 2.5 mg tocilizumab showed similar effect of decreasing CNV under the same dosage. [36] Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits VEGF-A isoforms. Researches showed that topical or subconjunctival administration of ranibizumab had the effect of suppressing CNV formation.…”

Section: Anti-vegf Antibodymentioning

confidence: 99%

“…Anti-VEGF antibody Bevacizumab [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] VEGF Tocilizumab [35,36] VEGF Ranibizumab [37][38][39][40][41][42] VEGF Pegaptanib [43][44][45] VEGF Drugs inhibit VEGF expression SiRNA [50][51][52][53] VEGF miR-184 [54,55] VEGF, PDGF-β, friend of Gata 2, phosphatidic acid phosphatase 2b antagomir-21 [56] miR-21, VEGF-A, HIF-1α…”

Section: Classification Drugs Main Targetsmentioning

confidence: 99%

See 2 more Smart Citations

Recent drug therapies for corneal neovascularization

Liu

Wang

et al. 2017

Chem Biol Drug Des

View full text Add to dashboard Cite

Corneal neovascularization (CNV) is a common pathological change in ocular surface diseases. It is not only the factor that affects vision but also the main cause for corneal graft failure. Based on the mechanism of CNV, many achievements have been developed to suppress the formation of CNV. There are certain novel drugs such as aflibercept, gold nanoparticles, and netrins which provide us with new clues to treat CNV. However, we still need to develop more effective therapeutic drugs. It is of great significance to develop new effective drugs to suppress the occurrence of CNV. In this paper, recent drug therapies for CNV are reviewed. The electronic database (PubMed) is searched for relative basic research and randomized clinical trials that are published recently.

show abstract

Section: The Drug Treatment Of Cnvmentioning

confidence: 85%

Section: Anti-vegf Antibodymentioning

confidence: 99%

Section: Classification Drugs Main Targetsmentioning

confidence: 99%

See 1 more Smart Citation

Recent drug therapies for corneal neovascularization

Liu

Wang

et al. 2017

Chem Biol Drug Des

View full text Add to dashboard Cite

show abstract

“…There is limited literature describing the use of voriconazole by SCo injection in horses. Reports of the use of this route with drugs other than voriconazole have proven to provide therapeutic concentrations to the anterior segment of the eye [48][49][50]. The topical 1% voriconazole treatment was considered a positive (standard treatment in clinical field) control to validate AH concentrations of voriconazole in this group of horses and as a comparison to previously published results [4].…”

Section: Discussionmentioning

confidence: 99%

Sustained-release voriconazole-thermogel for subconjunctival injection in horses: ocular toxicity and in-vivo studies

et al. 2020

View full text Add to dashboard Cite

Background: Keratomycosis is a relatively common, sight threatening condition in horses, where treatment is often prolonged and costly. Subconjunctival (SCo) injections offer less resistance to drug diffusion than the topical route, resulting in better penetration to the ocular anterior segment. Voriconazole, a second generation triazole antifungal, is effective against common fungal organisms causing keratomycosis. If combined with a thermogel biomaterial, voriconazole can be easily injected in the SCo space to provide sustained drug release. The purpose of this study was to evaluate the drug concentrations in the anterior segment and clinical effects after SCo injections of voriconazole-containing thermogel: poly (DL-lactide-co-glycolide-b-ethylene glycol-b-DL-lactide-co-glycolide) (PLGA-PEG-PLGA) in healthy equine eyes. Results: Voriconazole aqueous humor (AH) and tear concentrations were compared between 6 horses, receiving 1% voriconazole applied topically (0.2 mL, q4h) (Vori-Top) or 1.7% voriconazole-thermogel (0.3 mL) injected SCo (Vori-Gel). For the Vori-Gel group, voriconazole concentrations were measured in AH and tears at day 2 and then weekly for 23 days, and at day 2 only for the Vori-Top group. Ocular inflammation was assessed weekly (Vori-Gel) using the modified Hackett-McDonald scoring system. Ocular tissue concentrations of voriconazole following SCo 1.7% voriconazole-thermogel (0.3 mL) injections were evaluated post euthanasia in 6 additional horses at 3 different time points. Three horses received bilateral injections at 2 h (n = 3, right eye (OD)) and 48 h (n = 3, left eye (OS)) prior to euthanasia, and 3 horses were injected unilaterally (OS), 7 days prior to euthanasia. Voriconazole-thermogel was easily injected and well tolerated in all cases, with no major adverse effects. On day 2, drug concentrations in tears were higher in the Vori-Top, but not statistically different from Vori-Gel groups. For the Vori-Gel group, voriconazole was non-quantifiable in the AH at any time point. Total voriconazole concentrations in the cornea were above 0.5 μg/g (the target minimum inhibitory concentration (MIC) for Aspergillus sp.) for up to 48 h; however, concentrations were below this MIC at 7 days post treatment. Conclusions: Voriconazole-thermogel was easily and safely administered to horses, and provided 48 h of sustained release of voriconazole into the cornea. This drug delivery system warrants further clinical evaluation.

show abstract

“…Currently, steroids and other anti-inflammatory drugs are widely used, but these treatments are associated with unstable efficacies and significant side effects ( 33 ). Anti-VEGF biological agents have shown effective therapeutic effects in numerous ocular diseases ( 34 – 36 ). However, these biological agents are accompanied by severe complications in the eye, such as delaying epithelial wound healing and persistent epithelial defects or even corneal dissolution ( 2 , 37 , 38 ).…”

Section: Discussionmentioning

confidence: 99%